Enanta Pharmaceuticals, Inc. (ENTA) Social Stream



Enanta Pharmaceuticals, Inc. (ENTA): $39.47

1.34 (+3.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ENTA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 396

in industry

Featured Post From StockTwits About ENTA

$ENTA New Press Release:

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dosed the first subject in its Phase 1 clinical trial of EDP-721, a novel, oral hepatitis B virus (HBV) RNA destabilizer being developed for use in an all-oral combination regimen for chronic HBV patients. “We are pleased to advance our HBV program by dosing the first subject in our Phase 1 clinical st (...)

https://wchr.one/114238
WebChronicleToday, published August 16, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4266 seconds.